Access the full text.
Sign up today, get DeepDyve free for 14 days.
Accessed April 28, 2023 from mdcalc
C. Jenkinson, C. Brennan, R. Fitzpatrick, M. Bromberg, M. Swash (1999)
Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/ motor neurone disease: the ALSAQ-40Journal of Neurology, 246
D. Osoba, J. Pater (1993)
Assessing quality of life in clinical trials.Annals of oncology : official journal of the European Society for Medical Oncology, 4 6
Xiaojiao Xu, Dingding Shen, Yining Gao, Qinming Zhou, Y. Ni, Huan-yu Meng, H. Shi, W. Le, Sheng Chen, Sheng Chen (2021)
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?Translational Neurodegeneration, 10
(2020)
The Amyotrophic Lateral Sclerosis Health Index (ALS-HI): a measure of prioritized symptomatic themes in ALS
Christine Zizzi, J. Seabury, S. Rosero, Danae Alexandrou, Ellen Wagner, Jennifer Weinstein, A. Varma, N. Dilek, John Heatwole, J. Wuu, J. Caress, R. Bedlack, V. Granit, J. Statland, P. Mehta, M. Benatar, C. Heatwole (2022)
Patient reported impact of symptoms in amyotrophic lateral sclerosis (PRISM-ALS): A national, cross-sectional studyeClinicalMedicine, 55
Christina Fournier, R. Bedlack, C. Quinn, J. Russell, D. Beckwith, Kathleen Kaminski, W. Tyor, V. Hertzberg, Virginia James, M. Polak, J. Glass (2019)
Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).JAMA neurology
C. Jenkinson, R. Fitzpatrick (2001)
Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5Journal of Neurology, Neurosurgery & Psychiatry, 70
Gehrig's disease) j Mass
P. Mehta, J. Raymond, Reshma Punjani, M. Han, T. Larson, W. Kaye, Lorene Nelson, B. Topol, O. Muravov, Corina Genson, D. Horton (2022)
Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017Amyotrophic lateral sclerosis & frontotemporal degeneration, 24
(2009)
Guidance for industry: Patient-reported outcome measures: use in medical product development to support Labelling Claims. U.S. Department of Health and Human Services, Food and Drug Administration
Abstract Objective: The identification of effective therapeutics for ALS necessitates valid and responsive outcome measures to track disease progression and therapeutic gain in clinical trial settings. The Amyotrophic Lateral Sclerosis-Health Index (ALS-HI) is a multifaceted, disease-specific patient-reported outcome measure (PRO) designed to measure ALS symptomatic disease burden in adults with ALS. Methods: Through a national cross-sectional study of individuals with ALS, we identified the most important symptoms in ALS. These symptoms were incorporated into the ALS-HI, a measure that quantifies the multifaceted disease burden in ALS. We performed factor analysis, qualitative patient interviews, test-retest reliability assessment, and known groups analysis to evaluate and validate the ALS-HI. Results: The cross-sectional study included 497 participants with ALS who identified the most important symptoms to include in the ALS-HI. Fifteen participants beta tested the ALS-HI and found it to be clear, easy to use, and relevant. Twenty-one participants engaged in a test-retest reliability study, which indicated the reliability of the instrument (intraclass correlation coefficient = 0.952 for full instrument). The final ALS-HI and its subscales demonstrated a high internal consistency (Cronbach’s α = 0.981 for full instrument) and an ability to differentiate between groups with dissimilar disease severity. Conclusions: This research supports use of the ALS-HI as a valid, sensitive, reliable, and relevant PRO to assess the multifactorial disease burden faced by adults with ALS. The ALS-HI has potential as a mechanism to track disease progression and treatment efficacy during therapeutic trials.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration – Taylor & Francis
Published: Jul 3, 2023
Keywords: Amyotrophic lateral sclerosis; patient-reported outcome measure; disease burden; symptom assessment; therapeutic trial
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.